BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 9037359)

  • 21. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of metastatic seminoma by chemotherapy.: an experience].
    Komatsubara S; Itoi T; Watanabe M; Kitamura Y; Koike T
    Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):666-72. PubMed ID: 11109817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
    de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
    J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
    Hartmann JT; Kuczyk MA; Kollmannsberger C; Kanz L; Bokemeyer C
    World J Urol; 1999 Oct; 17(5):324-33. PubMed ID: 10552153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis.
    Childs WJ; Nicholls EJ; Horwich A
    Ann Oncol; 1992 Apr; 3(4):291-6. PubMed ID: 1382552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
    Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of pediatric germ cell tumor with comparison of carboplatin and cisplatin based regimens: A 10-year analysis.
    Jain R; Menon P; Bansal D; Kakkar N; Radhika S; Rao KLN; Trehan A
    Pediatr Hematol Oncol; 2022 Apr; 39(3):267-277. PubMed ID: 34665989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy for good-risk germ-cell tumors.
    Ryan CJ; Bajorin DF
    Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment.
    Weissbach L; Bussar-Maatz R; Flechtner H; Pichlmeier U; Hartmann M; Keller L
    Eur Urol; 2000 May; 37(5):582-94. PubMed ID: 10765098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
    Behnia M; Foster R; Einhorn LH; Donohue J; Nichols CR
    Eur J Cancer; 2000 Mar; 36(4):472-5. PubMed ID: 10717522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
    Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
    J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
    J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
    J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
    Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
    J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors.
    Stern JW; Bunin N
    Med Pediatr Oncol; 2002 Sep; 39(3):163-7. PubMed ID: 12210444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG).
    Germà-Lluch JR; Garcia del Muro X; Tabernero JM; Sánchez M; Aparicio J; Alba E; Barnadas A
    Ann Oncol; 1999 Mar; 10(3):289-93. PubMed ID: 10355572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
    de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
    Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.